The therapeutic effects of intraperitoneal topotecan, a water-soluble camptothecin analogi, wer investted in two models of human ovaran carcioma xenografted inaperitoneally into nude mice: the IGROV-1 tumour, which originated from an untreated patient, and the A2780 tumour, selected for ristance in vitro to cisplatin (A278ODDP). In IGROV-1 tumour-bearing mice, the optimal dose (10mgkg'1) of topotecan, given intapertoneally every 4 days for four ocmsions markedly incrased survival time over control mice (300 TIC'!.) and cured 4/9 mice, and such effects were not achieved by any of the clnically available drugs tested, i.e. cisplatin, carboplatin and doxorubin delvered intraperitoneally according to their optimal doses and In the tratment of A278ODDP tumour-bearing mice, topotecan was very effective since, at dose klvels of 6.6 and 10 mg kgI every 4 days for four occasions, 15/18 mice survived more than 100 days, and most of them (12/15) were found to be tumour free. The high responsiveness of this tumour to topotecan might be related to the elevated expon of the targt enzyme topoisomerase I. From these results, intraperitoneal treatment with topotecan appears to be a promisng approach in the therapy of refractory ovranan cancer confined to the peritoneal cavty.
Siay
The therapeutic effects of intraperitoneal topotecan, a water-soluble camptothecin analogi, wer investted in two models of human ovaran carcioma xenografted inaperitoneally into nude mice: the IGROV-1 tumour, which originated from an untreated patient, and the A2780 tumour, selected for ristance in vitro to cisplatin (A278ODDP). In IGROV-1 tumour-bearing mice, the optimal dose (10mgkg'1) of topotecan, given intapertoneally every 4 days for four ocmsions markedly incrased survival time over control mice (300 TIC'!.) and cured 4/9 mice, and such effects were not achieved by any of the clnically available drugs tested, i.e. cisplatin, carboplatin and doxorubin delvered intraperitoneally according to their optimal doses and In the tratment of A278ODDP tumour-bearing mice, topotecan was very effective since, at dose klvels of 6.6 and 10 mg kgI every 4 days for four occasions, 15/18 mice survived more than 100 days, and most of them (12/15) (Ozols, 1992) , selection of the appropriate drug appears to be critical for optimisation of this approach (Markman, 1986) .
Camptothecins, known as DNA topoisomerase I (topo I) inhibitors (Liu, 1989) , represent a new class of anti-tumour agent of particular interest because in preclinical studies they were found to be effective in the treatment of intrinsically resistant tumours (including melanoma and colon carcinoma) (Giovanella et al., 1989 (Giovanella et al., , 1991 and showed a broad spectrum of activity (Johnson et al., 1992) . Their clinical use is still hmited by systemic toxicities, including myelosuppression and gastrointestinal toxicity. In preclinical evaluation and in preliminary clinical studis, these agents were found to be devoid of local toxicity when mn rd by the i.p. and intramuscular routes (Giovanella et al., 1991; Houghton et al., 1992; Plaxe et al., 1993) . Topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin), -I piperidinolcarbonyloxycamptothecin) and 9-aminocamptothecin were selected for dinical development (Slichenmyer et al., 1993) .
Human ovarian carcinomas have been successfully xenografted into nude athymic mice subcutaneously (Friedlander et al., 1985; Kleine, 1986) and i.p. (Ward et al., 1987; Pratesi et al., 1990a Briefly, total RNA (20 ptg) was fractionated on a formaldehyde-containing 1% agarose gel and transferred to a Hybond-N filter. Hybridisations were carried out for 20 h at 42'C with denaturated random primed topo I or -y-actin probes (Juan et al., 1988; Miwa and Kamada, 1990) . The final wash of the filter was performed at 55°C in 0.5 x SSPE (3.6 M sodium chloride, 0.2 M sodium phosphate pH 7.7, 0.02 M disodium EDTA), and autoradiography was carried out at -70C on Amersham MP film. Topo I gene expression was quantified using a Phosphorlmager (Molecular Dynamics, Sunnyvale, CA, USA) by dividing the radioactivity of the transcnpt by that of the -tactin gene.
Resuts
The effect of i.p. topotecan on survival time of IGROV-1 tumour-bearing mice is shown in Figure 1 . Topotecan showed a dose-dependent effect, since 10 mg kg-' was the optimal dose when given every 4 days for four occasions, and 15 mg kg-I was toxic (five of nine mice died before the first control mouse). Figure 2 presents the effects of topotecan and cisplatin on the survival time of A278ODDP tumour-bearing mice. The drugs were delivered according to the same treatment schedule (every 4 days for four occasions). As expected, cisplatin produced only a marginal increase in mice MST (TIC'/o = 162) without inducing long-term survival. In contrast, all mice but one survived over 100 days in the group treated with the optimal dose of topotecan (10 mg kg'-), and all but two in the group treated with the lower dose (P < 0.001 for both topotecan doses vs cisplatin by two-sided Mann-Whitney rank test). At necropsy, 3 of the 15 sur- (Table II) . Figure 3 shows the levels of topoisomerase I expression in IGROV-1 and A2780 parent tumour lines and their cisplatinresistant variant. The A278ODDP tumour line, which was highly sensitive to topotecan, had the highest enzyme level. local tissue damage (i.e. typical local toxicity of most cytotoxic agents). Moreover, from this preclinical study, i.p. topotecan seems to be a very promising approach for future attempts to optimise treatment of ovarian cancer confined to the peritoneal cavity, as a consolidation therapy after a cisplatin-based treatment or as a second-line therapy for refractory disease.
